Expert Commentary and Research Insights GLP-1 Therapy Backed by Clinical Studies Brello Health's treatment approach is built on the growing body of evidence supporting GLP-1 receptor agonists, such as semaglutide and tirzepatide, for weight management
By using this enzymatic method to tie off the ends, we are essentially hiding the peptide from some of the most common proteases in the bodywhich are what breaks down peptides
At 5 units for the starting dose, each unit represents 50 mcg
So in general, there is a very nice effect, good effect on the vascular system, and of course, the vascular system is common for the entire body, so the kidneys and the liver and the heart and what have you, everything, also the brain
Another real-world study published in PMC examined patients with type 2 diabetes and confirmed that tirzepatide users had greater HbA1c and weight reductions at 12 months compared to injectable semaglutide users, regardless of whether they had previous GLP-1 receptor agonist experience